Skip to main content
. 2005 Aug 23;93(5):504–509. doi: 10.1038/sj.bjc.6602750

Table 3. Design of the main studies supporting 27a indications.

  No. %
Phase III RCT 14 52
NC-RCT 4 14
SAT 8 30
Otherb 1 4

RCT=randomised clinical trial; SAT=single-arm trial; NC-RCT=noncomparative RCT.

a

In at least two cases (docetaxel and doxorubicin pegylated), further comparative RCT were carried out to support preliminary findings.

b

Approval without empirical data, supported by bibliographic review of nonclinical and clinical data.